keyword
MENU ▼
Read by QxMD icon Read
search

radionuclide therapy

keyword
https://www.readbyqxmd.com/read/29777377/radiolabeled-f-ab-2-cetuximab-for-theranostic-purposes-in-colorectal-and-skin-tumor-bearing-mice-models
#1
P-S Bellaye, M Moreau, O Raguin, A Oudot, C Bernhard, J-M Vrigneaud, L Dumont, D Vandroux, F Denat, A Cochet, F Brunotte, B Collin
PURPOSE: This study aimed to investigate theranostic strategies in colorectal and skin cancer based on fragments of cetuximab, an anti-EGFR mAb, labeled with radionuclide with imaging and therapeutic properties, 111 In and 177 Lu, respectively. METHODS: We designed F(ab')2 -fragments of cetuximab radiolabeled with 111 In and 177 Lu. 111 In-F(ab')2 -cetuximab tumor targeting and biodistribution were evaluated by SPECT in BalbC nude mice bearing primary colorectal tumors...
May 17, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29774076/the-human-somatostatin-receptor-type-2-as-an-imaging-and-suicide-reporter-gene-for-pluripotent-stem-cell-derived-therapy-of-myocardial-infarction
#2
Katrien Neyrinck, Natacha Breuls, Bryan Holvoet, Wouter Oosterlinck, Esther Wolfs, Hubert Vanbilloen, Olivier Gheysens, Robin Duelen, Willy Gsell, Ivo Lambrichts, Uwe Himmelreich, Catherine M Verfaillie, Maurilio Sampaolesi, Christophe M Deroose
Rationale: Pluripotent stem cells (PSCs) are being investigated as a cell source for regenerative medicine since they provide an infinitive pool of cells that are able to differentiate towards every cell type of the body. One possible therapeutic application involves the use of these cells to treat myocardial infarction (MI), a condition where billions of cardiomyocytes (CMs) are lost. Although several protocols have been developed to differentiate PSCs towards CMs, none of these provide a completely pure population, thereby still posing a risk for neoplastic teratoma formation...
2018: Theranostics
https://www.readbyqxmd.com/read/29771460/targeting-prostate-cancer-prostate-specific-membrane-antigen-based-diagnosis-and-therapy
#3
REVIEW
Till Wüstemann, Uwe Haberkorn, John Babich, Walter Mier
The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic strategies. Prostate tumors specifically express the prostate-specific membrane antigen (PSMA), a membrane-bound protease. As PSMA is highly overexpressed on malignant prostate tumor cells and as its expression rate correlates with the aggressiveness of the disease, this tumor-associated biomarker provides the possibility to develop new strategies for diagnostics and therapy of PCa. Major advances have been made in PSMA targeting, ranging from immunotherapeutic approaches to therapeutic small molecules...
May 17, 2018: Medicinal Research Reviews
https://www.readbyqxmd.com/read/29770603/t-cell-tracking-using-cerenkov-and-radioluminescence-imaging
#4
F Boschi, F De Sanctis, S Ugel, A E Spinelli
Cancer immunotherapy is a promising strategy based on the ability of the immune system to kill selected cells. In the development of an effective T-cell therapy the non-invasive cell tracking methods play a crucial role. Here we investigate the potentialities of T-cell marked with radionuclides in order to detect their localization with imaging techniques in small animal rodents. A protocol to label T-cells with 32 P-ATP was tested and evaluated. The homing of 32 P-ATP labeled T lymphocytes was investigated by Cerenkov luminescence imaging and radioluminescence imaging The first approach relies on the acquisition of Cerenkov photons produced by the beta particles emitted by the 32 P internalized by lymphocytes; the second one on the detection of photons coming from the conversion of radioactive energy in light done by scintillator crystals layered on the animals...
May 16, 2018: Journal of Biophotonics
https://www.readbyqxmd.com/read/29766354/image-based-spect-calibration-based-on-the-evaluation-of-the-fraction-of-activity-in-the-field-of-view
#5
Adrien Halty, Jean-Noël Badel, Olga Kochebina, David Sarrut
BACKGROUND: SPECT quantification is important for dosimetry in targeted radionuclide therapy (TRT) and the calibration of SPECT images is a crucial stage for image quantification. The current standardized calibration protocol (MIRD 23) uses phantom acquisitions to derive a global calibration factor in specific conditions. It thus requires specific acquisitions for every clinical protocols. We proposed an alternative and complementary image-based calibration method that allows to determine a calibration factor adapted to each patient, radionuclide, and acquisition protocol and that may also be used as an additional independent calibration...
May 16, 2018: EJNMMI Physics
https://www.readbyqxmd.com/read/29766246/comparison-of-68-ga-ga-psma-11-pet-ct-with-18-f-naf-pet-ct-in-the-evaluation-of-bone-metastases-in-metastatic-prostate-cancer-patients-prior-to-radionuclide-therapy
#6
Christian Uprimny, Anna Svirydenka, Josef Fritz, Alexander Stephan Kroiss, Bernhard Nilica, Clemens Decristoforo, Roland Haubner, Elisabeth von Guggenberg, Sabine Buxbaum, Wolfgang Horninger, Irene Johanna Virgolini
AIM: The purpose of this study was to investigate the diagnostic performance of 68 Ga-PSMA-11 PET/CT in the evaluation of bone metastases in metastatic prostate cancer (PC) patients scheduled for radionuclide therapy in comparison to [18 F]sodium fluoride (18 F-NaF) PET/CT. METHODS: Sixteen metastatic PC patients with known skeletal metastases, who underwent both 68 Ga-PSMA-11 PET/CT and 18 F-NaF PET/CT for assessment of metastatic burden prior to radionuclide therapy, were analysed retrospectively...
May 16, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29762244/brca2-mutation-as-a-possible-cause-of-poor-response-to-177lu-psma-therapy
#7
Hojjat Ahmadzadehfar, Florian Gaertner, Philipp S Lossin, Bettina Schwarz, Markus Essler
We present the case of a 66-year-old man with castration-resistant prostate cancer, with an increasing prostate-specific antigen level, and a progressive disease during Lu-PSMA radionuclide therapy. Because the patient had a BRCA2 mutation, poly-ADP ribose polymerase inhibitor therapy was started. The patient showed a dramatic subjective and biological response to this therapy with a progression-free survival of 5 months.
May 14, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29762236/acute-pancreatitis-following-peptide-receptor-radionuclide-therapy-an-unusual-adverse-event
#8
Ioannis Karfis, Gwennaëlle Marin, Godelieve Machiels, Alain Hendlisz, Patrick Flamen
A 54-year-old man with grade 2 rectal neuroendocrine tumor and hepatic, pancreatic, and bone metastases was treated with Lu-DOTATATE as second-line therapy, after failure of somatostatin analogues. Two weeks after the first injection, he presented at the emergency department with acute pancreatitis. We hypothesized that this unusual adverse event, never been reported so far, was the result of acute tumor irradiation after PRRT, leading to peritumoral inflammation and edema with obstruction of an accessory pancreatic duct...
May 14, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29761524/the-24th-annual-prostate-cancer-foundation-scientific-retreat-report
#9
REVIEW
Andrea K Miyahira, Howard R Soule
INTRODUCTION: The 24th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 5-7, 2017, at the Omni Shoreham Hotel in Washington, DC. METHODS: The PCF Scientific Retreat is a scientific conference that specifically focuses on cutting edge research deemed to have significant promise for accelerating advances in prostate cancer biology and treatment. RESULTS: Themes highlighted at this year's meeting included: (i) new understandings in prostate cancer biology and disease progression; (ii) new mechanisms and treatment targets in advanced prostate cancer; (iii) advances in precision medicine genomics, germline genetics, and selection of targeted therapies; (iv) PSMA-targeted agents for PET imaging and radionuclide therapy; (v) approaches for improving the efficacy of immunotherapy in prostate cancer; (vi) applications of 3D Genomics in prostate cancer research; and (vii) potential applications of artificial intelligence in prostate cancer...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29761277/treatment-of-differentiated-thyroid-cancer-can-endoscopic-thyroidectomy-via-a-chest-breast-approach-achieve-similar-therapeutic-effects-as-open-surgery
#10
Rui Qu, Jinyi Li, Jingge Yang, Peng Sun, Jian Gong, Cunchuan Wang
BACKGROUND: An analysis of some special factors was performed to further evaluate and discuss whether endoscopic surgery and traditional open surgery have similar therapeutic outcomes for differentiated thyroid cancer (DTC). METHODS: A retrospective study was performed on 76 patients undergoing surgery to treat DTC. Forty patients were treated by endoscopic thyroidectomy via the chest-breast approach (endoscopic group) and thirty-six patients were treated by open surgery (open group)...
May 14, 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/29759083/hypertrophic-osteoarthropathy-mimicking-a-reactive-arthritis-a-case-report-and-review-of-the-literature
#11
Francesco Bozzao, Stella Bernardi, Franca Dore, Lorenzo Zandonà, Fabio Fischetti
BACKGROUND: Hypertrophic osteoarthropathy (HOA) is a syndrome characterized by abnormal proliferation of skin and periosteal tissues of the extremities. It can be a rare hereditary disease (pachydermoperiostosis) or can be secondary to various diseases, though mostly lung malignancies. Here, we report an unusual clinical presentation of HOA. CASE PRESENTATION: A 77-year-old man presented with fever, diarrhea, and an oligoarthritis involving the left knee and the ankles...
May 14, 2018: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29757620/separation-of-protactinium-employing-sulfur-based-extraction-chromatographic-resins
#12
Tara Mastren, Benjamin W Stein, T Gannon Parker, Valery Radchenko, Roy Copping, Allison Owens, Lance E Wyant, Mark Brugh, Stosh A Kozimor, F Meiring Nortier, Eva R Birnbaum, Kevin D John, Michael Ernst-Heinrich Fassbender
Protactinium-230 (t1/2 17.4 d) is the parent isotope of 230U (t1/2 20.8 d), a radionuclide of interest for targeted alpha therapy (TAT). Column chromatographic methods have been developed to separate no-carrier-added 230Pa from proton irradiated thorium targets and accompanying fission products. Results reported within demonstrate the use of novel sulfur bearing chromatographic extraction resins for the selective separation of protactinium. The recovery yield of 230Pa was 93 ± 4 % employing a R3P=S type commercially available resin and 88 ± 4 % employing a DGTA (diglycothioamide) containing custom synthesized extraction chromatographic resin...
May 14, 2018: Analytical Chemistry
https://www.readbyqxmd.com/read/29755915/unusual-long-survival-with-a-giant-invasive-pheochromocytoma-of-an-incompatible-patient
#13
Asli Nar
Pheochromocytomas (PHEOs) are rare neuroendocrine tumors and about 2-13% of PHEOs are malignant. Predicting malignancy in PHEO cases with invasion but without metastasis is still controversial in the literature. This study presents an unusual long survival with a giant invasive PHEO in an incompatible patient and a review of the literature. In 1989, a 23-year-old female patient was operated for a giant adrenal mass with a pathological final diagnosis of PHEO. Information to the patient's family was provided about the short life span of the patient in the postoperative period because the tumor could not be totally resected...
March 13, 2018: Curēus
https://www.readbyqxmd.com/read/29752180/-177-lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-lupsma-trial-a-single-centre-single-arm-phase-2-study
#14
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
BACKGROUND: Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are urgently needed. Lutetium-177 [177 Lu]-PSMA-617, a radiolabelled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA) enabling beta particle therapy targeted to metastatic castration-resistant prostate cancer. We aimed to investigate the safety, efficacy, and effect on quality of life of [177 Lu]-PSMA-617 in men with metastatic castration-resistant prostate cancer who progressed after standard treatments...
May 7, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29748550/novel-method-for-rapid-toxicity-screening-of-magnetic-nanoparticles
#15
A Erofeev, P Gorelkin, A Garanina, A Alova, M Efremova, N Vorobyeva, C Edwards, Y Korchev, A Majouga
Iron oxide nanoparticles have attracted a great deal of research interest and have been widely used in bioscience and clinical research including as contrast agents for magnetic resonance imaging, hyperthermia and magnetic field assisted radionuclide therapy. It is therefore important to develop methods, which can provide high-throughput screening of biological responses that can predict toxicity. The use of nanoelectrodes for single cell analysis can play a vital role in this process by providing relatively fast, comprehensive, and cost-effective assessment of cellular responses...
May 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29742602/impressive-response-to-tandem-treatment-with-90y-dotatoc-and-177lu-dotatoc-in-grade-3-pancreatic-neuroendocrine-carcinoma
#16
Alice Lorenzoni, Antonella Capozza, Salvatore Artale, Marco Maccauro, Ettore Cesare Seregni
Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response...
May 7, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29742518/immune-checkpoint-inhibitors-in-the-treatment-of-patients-with-neuroendocrine-neoplasia
#17
Matthias M Weber, Christian Fottner
BACKGROUND: Well-differentiated neuroendocrine neoplasms (NENs) are usually controlled by antiproliferative, local ablative and/or radionuclide therapies, whereas poorly differentiated NENs generally require cytotoxic chemotherapy. However, treatment options for patients with advanced/metastatic high-grade NENs remain limited. METHOD: Review of the literature and international congress abstracts on the efficacy and safety of immunotherapy by checkpoint inhibition in advanced/metastatic NENs...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29741203/peptide-receptor-radionuclide-therapy-for-advanced-gastroenteropancreatic-neuroendocrine-tumors-from-oncology-perspective
#18
Agnieszka Kolasińska-Ćwikła, Anna Łowczak, Katarzyna Maciejkiewicz Maciejkiewicz, Jarosław Bogdan Ćwikła
Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (somatostatin analogue - SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e.g. arising from the small bowel (often called carcinoid tumours), the pancreas, duodenum or stomach, but also from the large bowel or the lung and many other tissues (so called diffuse neuroendocrine system)...
2018: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/29726411/activation-of-qa-devices-and-phantom-materials-under-clinical-scanning-proton-beams-a-gamma-spectrometry-study
#19
Tereza Hanušová, Kamila Johnová, Matěj Navrátil, Jiří Valenta, Lutz Müller
Activation of detectors and phantoms used for commissioning and quality assurance of clinical proton beams may lead to radiation protection issues. Good understanding of the activation nuclide vectors involved is necessary to assess radiation risk for the personnel working with these devices on a daily basis or to fulfill legal requirements regarding transport of radioactive material and its release to the public. Eleven devices and material samples were irradiated with a 220 MeV proton pencil beam (PBS, Proton Therapy Center, Prague)...
May 4, 2018: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/29725717/highlights-of-the-30th-annual-congress-of-the-eanm-vienna-2017-yes-we-can-make-nuclear-medicine-great-again
#20
REVIEW
Stefano Fanti, Rachele Bonfiglioli, Clemens Decristoforo
The 30th Annual Congress of the European Association of Nuclear Medicine (EANM) was held in Vienna, Austria, from 21 to 25 October 2017 under the chairmanship of Professor Francesco Giammarile. As always, the Congress was a great success: more than 6,379 participants came from 90 countries from all continents. Participants were presented with an excellent programme consisting of symposia, and scientific and featured sessions, CME sessions, and plenary lectures. These lectures were devoted to nuclear medicine imaging and therapy, including hybrid imaging and molecular life sciences...
May 3, 2018: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
100899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"